Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effects of Alpha Lipoic Acid Supplementation on Serum Lipid Profile in Patients With Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Publisher



Ahmadi M1 ; Keshavarz SA2 ; Abbasi B1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Nutrition, Electronic Health and Statistics Surveillance Research Center, Islamic Azad University, Science and Research Branch, Tehran, Iran
  2. 2. Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran

Source: ARYA Atherosclerosis Published:2022


Abstract

BACKGROUND: Alpha lipoic acid (ALA) is considered a strong antioxidant with anti-inflammatory properties. Moreover, a number of previous studies have shown its lipid-lowering properties. Therefore, we designed this study to investigate the effects of ALA on lipid profile in patients with metabolic syndrome (MetS), which can lead to an increased risk of cardiovascular disease (CVD) and premature mortality. METHODS: A total 46 patients with MetS were randomly divided into two groups. They received either 600 mg ALA (n = 23) or 600 mg placebo (n = 23) for 12 weeks. The body weight, height, body mass index (BMI), waist circumference (WC), fasting blood sugar (FBS), hemoglobin A1C (HbA1c), and blood pressure (BP) were assessed at baseline of the study. Physical activity level and dietary intake were assessed at baseline and end of the study. Serum lipid profile including triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and total cholesterol (TC) were measured before and after 12 weeks of intervention. RESULTS: Baseline characteristics were similar in the ALA and placebo groups (P > 0.05). However, there were statistically significant differences in plasma levels of TG (-36.82 ± 42.48 versus 6.15 ± 25.04 mg/dl, P = 0.001) and TC (-8.91 ± 20.65 versus 10.84 ± 22.97 mg/dl, P = 0.01) after 12 weeks between the ALA group and the placebo group. Yet, there were no statistically significant differences in plasma levels of HDL-C and LDL-C after 12 weeks between the ALA group and the placebo group. CONCLUSION: The results suggest that daily supplementation of 600 mg ALA for 12 weeks may improve the lipid profile in patients with MetS. © 2022, Isfahan University of Medical Sciences(IUMS). All rights reserved.
Related Docs
1. Effect of Alpha-Lipoic Acid Supplementation on Lipid Profile: A Systematic Review and Meta-Analysis of Controlled Clinical Trials, Nutrition (2019)
2. The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-Pla2 Mass and Its Distribution Between Hdl and Apob-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial, Oxidative Medicine and Cellular Longevity (2020)
3. The Effect of Alpha-Lipoic Acid on Liver Function and Metabolic Markers in Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Controlled Trial, Iranian Red Crescent Medical Journal (2018)
4. Alpha-Lipoic Acid Supplement in Obesity Treatment: A Systematic Review and Meta-Analysis of Clinical Trials, Clinical Nutrition (2018)
5. Efficacy and Safety of Oral Alpha-Lipoic Acid Supplementation for Type 2 Diabetes Management: A Systematic Review and Dose– Response Meta-Analysis of Randomized Trials, Endocrine Connections (2022)
Experts (# of related papers)
View all Related Experts
Kurosh Djafarian (2)
Sakineh Shab-Bidar (2)